Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Insight Lifetech Debuts on Shanghai STAR Market with $3 Billion Valuation, Breaking Import Monopoly in Cardiovascular Imaging

Fineline Cube Feb 6, 2026
Company Deals

Knature Biopharmaceutical Files Hong Kong IPO to Advance Mitochondrial Medicine and NAD+ Therapeutics

Fineline Cube Feb 6, 2026
Company Deals Digital

XtalPi Partners with Visen Pharma to Accelerate AI‑Driven Endocrine Drug Discovery

Fineline Cube Feb 6, 2026
Company Deals

Shanghai Pharma to Divest 30% Stake in Sino-American Squibb for $147M

Fineline Cube Feb 6, 2026
Company Deals

Everest Medicines Licenses Micot’s MT1013 for Secondary Hyperparathyroidism in $178M Deal

Fineline Cube Feb 5, 2026
Policy / Regulatory

Guangdong Unveils Expanded 2025 Greater Bay Area Access List for 115 Hong Kong and Macao Drugs and Devices

Fineline Cube Feb 9, 2026
Company Drug

Delonix Bioworks’ DX-104 Becomes First China-Approved Engineered OMV Vaccine, Targets $1.3 Billion MenB Market

Fineline Cube Feb 9, 2026
Company Drug

Sino Biopharm Completes Phase III Enrollment for LM-302 ADC in Gastric Cancer

Fineline Cube Feb 9, 2026
Policy / Regulatory

NHC Releases Updated List of Pediatric Drugs for Research and Development Incentives

Fineline Cube Sep 10, 2024

The National Health Commission (NHC) has issued a notification regarding the fifth batch of pediatric...

Company Drug

Innovent Biologics’ Dupert Demonstrates Positive Results in Phase II NSCLC Trial

Fineline Cube Sep 10, 2024

Innovent Biologics, Inc. (HKG: 1801), a leading biopharmaceutical company based in China, has announced that...

Drug Policy / Regulatory

China’s CDE Issues Draft Guidelines for Biosimilar Pharmaceutical Similarity Research

Fineline Cube Sep 10, 2024

The Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has released...

Company Deals R&D

Tigermed Partners with Purpose Africa to Boost Clinical Research and Healthcare Cooperation

Fineline Cube Sep 9, 2024

Tigermed (SHE: 300347), a leading Contract Research Organization (CRO) in China, has entered into a...

Policy / Regulatory

China’s 2024 Negative List Eases Restrictions on Foreign Investment in TCM and Biotechnology

Fineline Cube Sep 9, 2024

The National Development and Reform Commission (NDRC) of China has announced the release of the...

Policy / Regulatory

China’s NMPA Proposes Inclusion of Cochlear Implants in Volume-Based Procurement Plans

Fineline Cube Sep 9, 2024

The National Medical Products Administration (NMPA) has disclosed plans to expand the scope of its...

Company Deals Medical Device

Edwards Lifesciences Sells ICU Business to BD in $4.2 Billion Deal, Announces Layoffs

Fineline Cube Sep 9, 2024

Edwards Lifesciences, a leading U.S. medical device company, has reportedly reached an agreement to sell...

Company Drug

Zelgen Biopharma’s ZG006 Shows Promising Anti-Tumor Efficacy in Phase I/II SCLC Study

Fineline Cube Sep 9, 2024

Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266), a biopharmaceutical company based in China, has announced...

Policy / Regulatory

China’s NHSA Proposes New Guidelines to Enhance Oversight of Medical Insurance Funds

Fineline Cube Sep 9, 2024

The National Healthcare Security Administration (NHSA) has unveiled a draft of the “Guiding Opinions on...

Company Deals

Caprico Biotechnologies and Mindray Medical Form Comprehensive Flow Testing Partnership

Fineline Cube Sep 9, 2024

Caprico Biotechnologies, Inc., a Chinese biotechnology company, has entered into a comprehensive partnership with Mindray...

Policy / Regulatory

China Opens Doors to Foreign Biotech and Wholly-Owned Hospitals in Healthcare Sector Expansion

Fineline Cube Sep 9, 2024

China’s Ministry of Commerce, National Health Commission, and National Medical Products Administration (NMPA) have jointly...

Company

Connect Biopharma Shifts Focus to US, Plans Further Reduction in China Workforce

Fineline Cube Sep 9, 2024

Connect Biopharma Holdings Ltd (NASDAQ: CNTB), a Sino-US biotechnology company that initially operated in Suzhou...

Policy / Regulatory

Guangzhou Health Commission Unveils Ten Measures to Boost Innovative Pharma and Medical Device Development

Fineline Cube Sep 9, 2024

On September 5, 2024, the Guangzhou Health Commission issued the “Guangzhou Health Commission’s Ten Measures...

Company Drug

Merck and Daiichi Sankyo’s Ifinatamab Deruxtecan Shows Promising Results in Phase II ES-SCLC Trial

Fineline Cube Sep 9, 2024

Merck, Sharp & Dohme Inc. (MSD, NYSE: MRK), a leading U.S. pharmaceutical company, and its...

Company Policy / Regulatory

Biosecure Act Faces Opposition from Senior House Democrat Jim McGovern

Fineline Cube Sep 9, 2024

The trajectory of the US Biosecure Act through the House of Representatives encountered unexpected turbulence...

Company Drug Policy / Regulatory

China’s CDE Releases 86th Batch of Reference Preparations for Generic Drug Evaluation

Fineline Cube Sep 9, 2024

China’s Center for Drug Evaluation (CDE) has unveiled its 86th roster of reference preparations for...

Company Drug

Akeso’s Ivonescimab Shows Promising Results in Phase III Clinical Trial for Hepatocellular Carcinoma

Fineline Cube Sep 9, 2024

Akeso Inc. (HKG: 9926), a biopharmaceutical company based in China, has announced that its first-in-class...

Company Legal / IP

AstraZeneca Faces Investigation in China Over Data Privacy and Unapproved Drugs

Fineline Cube Sep 6, 2024

AstraZeneca (NASDAQ: AZN), a leading UK pharmaceutical company, is reportedly under the spotlight in Shenzhen,...

Company Policy / Regulatory

U.S. House of Representatives to Review the Biosecure Act Amid Legislative Hurdles

Fineline Cube Sep 6, 2024

The U.S. House of Representatives is slated to take up the contentious Biosecure Act the...

Company Deals

Eli Lilly Partners with Genetic Leap for RNA-Targeted AI Drug Discovery

Fineline Cube Sep 6, 2024

Eli Lilly & Co. (NYSE: LLY), a leading pharmaceutical company based in the U.S., has...

Posts pagination

1 … 256 257 258 … 621

Recent updates

  • Delonix Bioworks’ DX-104 Becomes First China-Approved Engineered OMV Vaccine, Targets $1.3 Billion MenB Market
  • Peijia Medical Files CE Mark for GeminiOne TEER System in European Mitral Regurgitation Market
  • Novartis Breaks Ground on $23 Billion US Biomedical Research Center in San Diego
  • Sino Biopharm Completes Phase III Enrollment for LM-302 ADC in Gastric Cancer
  • Gilead’s Kite Pharma Secures FDA Label Expansion for Yescarta in Primary CNS Lymphoma
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Delonix Bioworks’ DX-104 Becomes First China-Approved Engineered OMV Vaccine, Targets $1.3 Billion MenB Market

Company Medical Device

Peijia Medical Files CE Mark for GeminiOne TEER System in European Mitral Regurgitation Market

Company

Novartis Breaks Ground on $23 Billion US Biomedical Research Center in San Diego

Company Drug

Sino Biopharm Completes Phase III Enrollment for LM-302 ADC in Gastric Cancer

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.